Growth hormone therapy. - Lyophilization Articles & Reports

Growth hormone therapy.
February 2005
Bajpai Anurag1, Menon P SN2
1 Division of Pediatric Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
2 Department of Pediatrics, Armed Forces Hospital, Kuwait
SYMPOSIUM ON GROWTH AND ITS DISORDERS | Volume : 72 | Issue : 2 | Page : 139-144
Please visit the web site to view the article in its entirety.
Abstract
rowth hormone (GH) therapy has revolutionized treatment of children with growth hormone deficiency (GHD). Improved height outcome with final height in the target height range has been achieved in these children. Identification of Creutzfeldt-Jakob disease, a deadly prion mediated disorder, in recipients of pituitary GH accelerated the transition from pituitary derived GH to recombinant GH. Once daily subcutaneous administration of the freeze-dried preparation at evening is the recommended mode of GH therapy. Studies have led to use of higher dose of GH for improving height outcome (0.33 mg/kg/week or 0.14 IU/kg/day) albeit at a significantly high cost. Growth velocity increases from 3-4 cm/year before therapy to 10-12 cm/year during the first two years of therapy and is maintained at 7-8 cm/year after a period of two years. Close follow-up with regular clinical and laboratory monitoring is essential for achieving a desirable height outcome. A theoretical unlimited supply has led to wide spread use of GH in a variety of disorders other than GHD. Initially started in children with Turner syndrome, GH has now been used in chronic renal failure, idiopathic short stature and intrauterine growth restriction besides a wide array of newly emerging indications.
Correspondence Address:
Menon P SN
Department of Pediatrics, Armed Forces Hospital, PO Box 5819, Salmiya 22069
Kuwait
References
1. Russo L, Moore WV. A comparison of subcutaneous and intramuscular administration of human growth hormone in therapy of human growth hormone deficiency. J Clin Endocrinol Metab 1982; 55: 1003-1006.
2. Wilson DM, Baker B, Hintz RL, Rosenfield RG. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatostatin response. Pediatrics 1985; 76: 361-364.
3. MacGillivary MH, Bapista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatotropin treatment in prepubertal na?ve growth hormone deficient children. J Clin Endocrinol Metab 1996; 81: 1806-1809.
4. Van Teunenbroek A, de Munick Keizer-Schrama S, Stijnen T et al. Growth response and levels of growth after two years growth hormone treatment are similar for once or twice daily regimen in girls with Turner syndrome. Clin Endocrinol (Oxford) 1997; 46: 451-459.
5. Zadik Z, Liberman E, Altman Y, Chen M, Limoni Y, Landau H. Effect of timing of growth hormone on plasma growth-hormone-binding activity, insulin like growth factor-1 and growth in children with subnormal secretion of growth hormone. Horm Res 1993; 39: 188-191.
6. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 2002; 15 (Suppl 2): 715-722.
7. Wit JM. Growth hormone therapy. Clinical Endocrinol Metab 2002; 16: 483-504.
8. Martha PM, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status and body mass. J Clin Endocrinol Metab 1992; 74: 336-344.
9. Hintz RL. Management of disorders of size. In Brook CGD, Hindmarsh PC, eds. Clinical Pediatric Endocrinology, 4th edn. London: Blackwell Science 2001; 124-139.
10. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertson-Wikland K, Price DA. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with GH deficiency. J Clin Endocrinol Metab 1999; 84: 1174-1183.
11. Muller V, Hoepffner W, Kiess W, Keller E. Prediction of height velocity of prepubertal children with growth hormone deficiency in the first year of treatment with recombinant human growth hormone. J Pediatr Endocrinol Metab 2000; 13: 893-897.
12. Radetti G, Buzi F, Paganini C, Pilotta A, Felappi B. Treatment of GH-deficient children with two different GH doses: effect on final height and cost-benefit implications. Eur J Endocrinol 2003; 148: 515-518.
13. Blethen SL, Bapista J, Kuntze J, Foley T, LaFranchi S, Johanson A. Adult height in growth hormone deficient children treated with biosynthetic GH: the Genetech growth study group. J Clin Endocrinol Metab 1997; 82: 418-420.
14. Tanaka T, Cohen P, Clayton PE, Laron Z, Hintz TL, Sizoneneko PC. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 2: Growth hormone treatment in growth hormone deficient children. Growth Horm IGF Res 2002; 12: 323-341.
15. Rosenfield GR, Cohen P. Disorders of growth hormone/insulin like growth factor and action. In Sperling MA, ed. Pediatric Endocrinology, 2nd edn. Philadelphia, WB Saunders, 2002; 211-288.
16. Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy- a review. Growth Horm IGF Res 2000; 10: 306-317.
17. Buckler JM. A longitudinal study of adolescent growth. London, Springer 1990.
18. Tanaka T, Konatsu K, Takada G, Miyashita M, Ohno T. Prediction of adult height in healthy Japanese children. Acta Pediatr 1996; 417 (suppl): 57-60.
19. Stanhope R, Uruena M, Hindmarsh P, Leiper AD, Brook CG. Management of growth hormone deficiency through puberty. Acta Pediatr Scand 1998; 372 (suppl): 47-52.
20. Albertson-Wikland K, Alm F, Aronsson S et al. Effect of growth hormone (GH) during puberty in GH-deficient children: preliminary results form an ongoing trial with different dose regimens. Acta Pediatr 1998; 428 (suppl): 80-84.
21. Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Katsumata N, Tachibana K, Nose O, Hibi I. When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue. Acta Pediatr 1999; Suppl 88: 85-88.
22. Merciq MV, Eggers M, Avila A, Cutler GB Jr, Cassorola F. Near final height in pubertal growth hormone (GH) deficient parents treated with GH alone or in combination with leutenizing releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000; 85: 569-573.
23. Cutfield WS, Lindberg A, Chatelain P et al. Final height following growth hormone treatment idiopathic growth hormone deficiency in KIGS. In Ranke MB, Wilton P, eds. Growth Hormone Therapy in KIGS- 10 Year Experience. Heidelberg 1999. Pp 93-109.
24. August GP, Julius JR, Blethen SL. Adult height in growth hormone deficient children treated with biosynthetic GH. The national cooperative growth study experience. Pediatrics 1998; 49: 80-85.
25. Cacciari E, Cicognani A, Pirazolli P et al. Final height of patients treated for isolated GH deficiency examination on 83 patients. Eur J Endocrinol 197; 137: 53-60.
26. Ranke MB, Price DA, Albertsson-Wikland K, Maes M, Lindbe A. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Horm Res 1997; 48: 62-71.
27. Burns EC, Tanner JM, Preece MA, Cameron N. Final height and pubertal development in 55 children with idiopathic growth hormone deficiency. Eur J Pediatr 1981; 137: 155-164.
28. Hibi I, Tanaka T. Final height of patients with idiopathic growth hormone deficiency after long-term growth hormone treatment. Committee for Treatment of Growth Hormone Deficient Children, Growth Science Foundation, Japan. Acta Endocrinol (Copenh) 1989; 120: 409-415.
29. Rikken MB, Massa GG, Wit JM. Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Horm Res 1997; 48: 62-71.
30. Tanaka T, Takano K, Igarashi Y et al. Growth hormone (GH) treatment and puberty in GH treated GH children. Clin Pediatr Endocrinol 1999; 8 (Suppl 12): 37-44.
31. Lampit M, Nave T, Hochberg Z. Water and sodium retention during short-term administration of growth hormone to short normal children. Horm Res 1998; 50: 83-88.
32. Watanabe S, Tsunematsu Y, Fujimoto J, Korniyama A. Leukemia in patients treated with growth hormone. Lancet 1989; 80: 822-825.
33. Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children with growth hormone: review and reanalysis. J Pediatr 1997; 131: S32-S36.
34. Nishi Y, Tanaka T, Takano K et al. Recent status in the occurrence of leukemia in growth hormone treated patients in Japan. J Clin Endocrinol Metab 1999; 84: 1961-1965.
35. Swerdkow AJ, Reddubgius RE, Higgins CD et al. Growth hormone treatment of children with brain tumors and risk of recurrence. J Clin Endocrinol Metab 2000; 85: 4444-4449.
36. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfield R. Safety of recombinant deoxyribonucleic acid derived growth hormone: the national cooperative growth study experience. J Clin Endocrinol Metab 1996; 81: 1704-1710.
37. Rappaport EB, Fife D. Slipped capital femoral epiphysis in growth hormone deficient patients. Am J Dis Child 1985; 139: 396-399.
38. Blethen SL, Rundle AC. Slipped capital femoral ephiphysis in children treated with growth hormone. Horm Res 1996; 46: 113-116.
39. Vahl N, Juul A, Jorgenesen JO et al. Continuation of growth hormone (GH) treatment I GH deficient patients during transition form childhood to adulthood: a two year placebo-controlled study. J Clinical Endocrinol Metab 2000; 85: 1874-1881.
40. Saggese G, Ranke MB, Saenger P et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after availability of recombinant growth hormone. Horm Res 1